Interpace Biosciences Sees Preliminary Q3 Revenue of $10.1M–$10.4M
The company expects unaudited Q3 2026 revenue of $10.1 million–$10.4 million, up about 11%–14% from Q2 2026 and 15%–18% from Q3 2025, subject to closing and review.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.